Every 10-K that Benitec Biopharma Inc. (BNTC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BNTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BNTC filings page.
Benitec Biopharma Inc. (BNTC), a clinical-stage gene therapy company focused on its BB-301 “silence and replace” program for oculopharyngeal muscular dystrophy (OPMD), reported higher operating expenses and losses for the fiscal year ended June 30, 2026 while strengthening its cash position via equity financings.
Research and development expenses were $23.4 million and general and administrative expenses were $27.8 million, bringing total operating expenses to $51.2 million, up from $41.8 million in 2025, largely due to higher share-based compensation and payroll. Net loss widened to $45.5 million, though net cash used in operating activities improved to $16.5 million. Benitec ended the year with $180.0 million in cash and cash equivalents, supported by $104.5 million in gross equity proceeds during the year, and estimates this balance will fund operations for at least the next twelve months as it advances the BB-301 Phase 1b/2a trial and prepares for a pivotal study.
Benitec Biopharma Inc. filed an amended annual report mainly to include the conformed signature of its independent auditor, updated exhibit references, and fresh CEO/CFO certifications, without changing the substantive disclosures from the original Form 10‑K.
For the year ended June 30, 2025, Benitec reported a net loss of $37.9 million versus $21.8 million a year earlier, driven by higher operating expenses of $41.8 million, including $18.3 million in research and development and $23.4 million in general and administrative costs. Share‑based compensation rose to $17.4 million. Cash, cash equivalents, and restricted cash increased to $97.9 million, supported by equity financings and warrant exercises providing $70.5 million of net proceeds in fiscal 2025 and an April 2024 PIPE that raised $40.0 million of gross proceeds. Stockholders’ equity grew to $97.3 million, with 26,250,469 common shares outstanding at June 30, 2025, and management believes existing cash will fund operations for at least the next twelve months.
Benitec Biopharma Inc. (BNTC) is an early-stage genetic medicines company developing BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 has received Orphan Drug Designation in the United States and the European Union and is in a Phase 1b/2a single-arm, open-label, sequential dose-escalation study (NCT06185673) with dosing delivered directly to pharyngeal muscles and interim safety/efficacy readouts expected at 180-day intervals.
Financially, the company reported $97.7 million in cash and cash equivalents as of June 30, 2025, used cash in operations of $23.6 million for the year, and raised material proceeds during the year (including a $40.0 million PIPE and additional offerings), with total net proceeds from issuances and warrant exercises during the fiscal year stated at $70.5 million. The company disclosed a restatement related to prior-period recognition of certain non-cash share-based compensation expenses and notes it will continue to incur operating losses and depend on financing to fund operations.